TY - JOUR
T1 - Gynecologic oncology in 2024
T2 - breakthrough trials and evolving treatment strategies for cervical, uterine corpus, and ovarian cancers
AU - Lee, Sung Jong
AU - Yoo, Ji Geun
AU - Kim, Jin Hwi
AU - Park, Jeong Yeol
AU - Lee, Jung Yun
AU - Lee, Yoo Young
AU - Suh, Dong Hoon
N1 - Publisher Copyright:
© 2025. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology, and Japan Society of Gynecologic Oncology.
PY - 2025/1
Y1 - 2025/1
N2 - This review summarized the results of clinical trials in 2024 that were believed to have a significant impact on clinical practice in the field of gynecologic oncology. The SHAPE trial, INTERLACE and KEYNOTE-A18 trials, and BEATcc and COMPASSION-16 trials were included in early-stage, locally advanced, and recurrent/metastatic cervical cancer, respectively. For uterine corpus cancer, updated survival data of the four trials (NRG-GY018, RUBY, AtTEnd, DUO-E) for endometrial cancer and the first survival data of LMS-04 trial for leiomyosarcoma were described. For ovarian cancer, the final overall survival results of PRIMA study were followed by DUO-O, ATHENA-combo, and FIRST-ENGOT-OV44 trial in different disease conditions. Finally, the results of DESTINY-PanTumor02, a basket trial of trastuzumab deruxtecan, were briefly addressed.
AB - This review summarized the results of clinical trials in 2024 that were believed to have a significant impact on clinical practice in the field of gynecologic oncology. The SHAPE trial, INTERLACE and KEYNOTE-A18 trials, and BEATcc and COMPASSION-16 trials were included in early-stage, locally advanced, and recurrent/metastatic cervical cancer, respectively. For uterine corpus cancer, updated survival data of the four trials (NRG-GY018, RUBY, AtTEnd, DUO-E) for endometrial cancer and the first survival data of LMS-04 trial for leiomyosarcoma were described. For ovarian cancer, the final overall survival results of PRIMA study were followed by DUO-O, ATHENA-combo, and FIRST-ENGOT-OV44 trial in different disease conditions. Finally, the results of DESTINY-PanTumor02, a basket trial of trastuzumab deruxtecan, were briefly addressed.
KW - Gynecologic Neoplasms
KW - Immunoconjugates
KW - Immunotherapy
KW - Molecular Targeted Therapy
KW - Poly(ADP-Ribose) Polymerase Inhibitor
UR - http://www.scopus.com/inward/record.url?scp=85217070871&partnerID=8YFLogxK
U2 - 10.3802/jgo.2025.36.e72
DO - 10.3802/jgo.2025.36.e72
M3 - Review article
C2 - 39900347
AN - SCOPUS:85217070871
SN - 2005-0380
VL - 36
JO - Journal of Gynecologic Oncology
JF - Journal of Gynecologic Oncology
IS - 1
M1 - e72
ER -
